Pediatric use of topical ophthalmic drugs

Area of Science:

• Ophthalmology
• Pediatric Pharmacology
• Regulatory Science

Background:

• Recent policy changes by the Food and Drug Administration (FDA) have led to a significant increase in FDA-approved medications for pediatric use.
• This includes a growing number of topical ophthalmic drugs indicated for treating allergies, inflammation, and infections in children.
• The trend of expanding pediatric drug approvals is expected to continue.

Purpose of the Study:

• To review the historical context of FDA oversight for pediatric drug approvals.
• To highlight recent shifts in FDA policies and their impact on pediatric drug labeling.
• To discuss specific considerations for ophthalmic drug use in children, including dosage, administration, and systemic effects.

Main Methods:

• Literature review of FDA policies and drug approvals.
• Analysis of pediatric ophthalmic drug data.
• Discussion of pharmacokinetic and pharmacodynamic differences in pediatric populations.

Main Results:

• A growing number of topical ophthalmic medications are now approved for pediatric use.
• Key differences in dosage, administration, distribution, systemic toxicity, and metabolism exist for pediatric ophthalmic drugs.
• A summary of currently approved topical ophthalmic drugs for pediatric use, with age considerations, is provided.

Conclusions:

• Healthcare providers must be aware of the expanding landscape of topical ophthalmic drugs approved for pediatric patients.
• Regulatory, social, and economic factors support the continued increase in pediatric drug approvals.
• Prescribing clinicians should meticulously consult product labeling for "Pediatric Use" indications and age-specific recommendations.